Changeflow GovPing Healthcare & Life Sciences oXiris Hemofilter in Septic Shock With AKI Trial
Routine Notice Added Final

oXiris Hemofilter in Septic Shock With AKI Trial

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registered a multicenter retrospective observational study (NCT07539883) evaluating the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury requiring continuous renal replacement therapy. The study uses a Target Trial Emulation approach to compare patients treated with oXiris® filters against standard CRRT filters, examining in-hospital mortality, fluid balance, and vasopressor requirements. The study addresses inconsistent evidence regarding whether oXiris® improves survival through endotoxin and cytokine removal.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new observational clinical trial (NCT07539883) on ClinicalTrials.gov describing a multicenter retrospective cohort study of the oXiris® hemofilter in septic shock patients with acute kidney injury. The study will use Target Trial Emulation methodology to compare outcomes between oXiris® filter patients and standard CRRT filter patients, focusing on in-hospital mortality, fluid balance, and vasopressor requirements. This is a registry entry documenting planned research and does not establish any regulatory requirements or compliance obligations. Healthcare institutions and researchers conducting or reviewing continuous renal replacement therapy studies may reference this trial design when evaluating similar evaluation approaches for extracorporeal cytokine removal devices.

Archived snapshot

Apr 20, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study

Observational NCT07539883 Kind: OBSERVATIONAL Apr 20, 2026

Abstract

This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.

Conditions: Septic Shock, Multiorgan Failure, Sepsis

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 20th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07539883

Who this affects

Applies to
Healthcare providers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Clinical trial evaluation Medical device research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!